Nivolumab
Antineoplastic Agents
Yana Najjarmonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the Antineoplastic Agents cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zofran Dr Atul Sharma | Phase 3 | BB |
(+)-VINCRISTINE Instituto do Cancer do Estado de São Paulo | Phase 3 | BB |
TRASTUZUMAB Incepta Pharmaceuticals Ltd | Phase 2 | BB |
Cetuximab Armando Orlandi | Phase 3 | B |
Carboplatin Blueprint Medicines Corporation | Phase 2 | B |
View all 25 →
Same molecule, other indications
Nivolumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →